Back to DE D. E. Shaw & Co., Inc.

AXSMAXSM

Showing 8 of 25 quarters

Position history for DED. E. Shaw & Co., Inc.'s holdings in Axsome Therapeutics, Inc.

Yes. D. E. Shaw holds 604,753 shares of AXSM (Axsome Therapeutics), worth $148M, as of its Q2 2026 13F filing. It increased the position by 1,288 shares (+0.2%) from Q1 2026. D. E. Shaw has held AXSM since Q4 2023, across 11 quarterly 13F filings. AXSM is 0.1% of D. E. Shaw's reported 13F portfolio.

Current Value

$148M

Current Shares

604,753

Total Value Change

+$147.8M

Total Shares Change

+601,853

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
604,753
+0.2%
$148M0.1%$244.77
30
2026-Q1
Increased
603,465
+9.9%
$102M0.1%$169.02
33
2025-Q4
Increased
549,113
+85.3%
$100.3M0.1%$182.64
47
2025-Q3
Increased
296,287
+47.6%
$36M0.0%$121.45
40
2025-Q2
Decreased
200,764
-63.3%
$21M0.0%$104.39
0
2025-Q1
Increased
547,665
+2591.8%
$63.9M0.1%$116.63
48
2024-Q4
Increased
20,346
+601.6%
$1.7M0.0%$84.61
41
2024-Q3
Decreased
2,900
-54.2%
$260,6230.0%$89.87
0

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used